Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Neuroprotection
100%
Intravitreal Injection
100%
Rodent Models
100%
Anterior Ischemic Optic Neuropathy
100%
Prostaglandin J2
100%
Optic Nerve
37%
Neuroprotective
37%
Intravitreal
37%
Retina
25%
Retinal Ganglion Cells
25%
Cell number
25%
Visual Evoked Potentials
25%
United States
12%
Nave
12%
Transmission Electron Microscopy
12%
Axon
12%
Immunohistochemistry
12%
Most Common Cause
12%
Systemic Administration
12%
Vision Loss
12%
Long-Evans Rats
12%
Euthanized
12%
Fellow Eye
12%
Route of Administration
12%
Contralateral Eye
12%
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
12%
Normal Adults
12%
Visual-evoked Potential Amplitude
12%
14-prostaglandin J2
12%
Quantitative Stereology
12%
Optic Nerve Edema
12%
Medicine and Dentistry
Intravitreal Administration
100%
Neuroprotection
100%
Arteritic Anterior Ischemic Optic Neuropathy
100%
Prostaglandin J2
100%
Optic Nerve
44%
Neuroprotective Agent
33%
Visual Evoked Potential
33%
Ganglion
22%
Contralateral
11%
Transmission Electron Microscopy
11%
Immunohistochemistry
11%
Visual Impairment
11%
Edema
11%
Systemic Administration
11%
Stereology
11%
Diseases
11%
Axon
11%
Nursing and Health Professions
Neuroprotection
100%
Intravitreal Drug Administration
100%
Anterior Ischemic Optic Neuropathy
100%
Prostaglandin J2
100%
Neuroprotective Agent
33%
Visual Evoked Potential
33%
Electroretinogram
22%
Cell Count
22%
Efficacy
22%
Visual Impairment
11%
Edema
11%
Immunohistochemistry
11%
Transmission Electron Microscopy
11%
Diseases
11%
Older Person
11%
Rat
11%
Stereology
11%
Neuroscience
Neuroprotection
100%
Optic Neuropathy
100%
Prostaglandin J2
100%
Optic Nerve
44%
Neuroprotective Agent
33%
Visual Evoked Potential
33%
Retinal Ganglion Cell
22%
Electroretinogram
22%
Immunohistochemistry
11%
Transmission Electron Microscopy
11%
Stereology
11%
Axon
11%